Emily Day

Senior Statistician II at AstraZeneca

[Emily Day @EmilyD_stats]

I’ve written a paper developing methods to adjust for verification bias in diagnostic accuracy measures when comparing multiple screening tests, and then applied these methods to IP1-PROSTAGRAM trial data https://t.co/fISj6sg6mg 📖 just published and incredibly proud!!! 🥳

[Emily Day @EmilyD_stats]

We published a paper exploring the results of cardiac surgery during the COVID-19 pandemic compared with previous years: a propensity weighted study of outcomes at six months - Give it a read! 📖 #propensityweighting #covid19 ⁦@Francy_lif⁩ https://t.co/HGdZlm2CPF

[Emily Day @EmilyD_stats]

Congratulations Dr @RachPips!! 🥳🥳

[StatsCI @stats_ci]

Congratulations to @RachPips who passed her PhD viva today, we are so very proud of you! #PhD #Congratulations 🎉🎉🎉✨✨✨👩‍🎓👩‍🎓👩‍🎓

[StatsCI @stats_ci]

New statistical analysis plan publication for feasibility phase of the CHRONOS study including 2 parallel randomised trials & the first MAMS surgical trial in #prostatecancer by @EmilyD_stats @Francy_lif et al #Trials https://t.co/UWL3py4d1G

[Emily Day @EmilyD_stats]

I’ve had such an amazing time working at ICTU over the past 2 and a half years! I’ll miss you all 🤗

[StatsCI @stats_ci]

From all of us x

[StatsCI @stats_ci]

Wishing you the best of luck Emily in your new role from all of us at ICTU. We will miss you very much.
🥂🍾🥂

[Emily Day @EmilyD_stats]

@stats_ci @VR_Cornelius Miss you all already! Thank you for a great send off 🥰

[StatsCI @stats_ci]

Join us June 8th to hear from @Deborah_Ashby & @RachPips discussing 'Improving treatments for patients: Why statisticians count' at the next @imperialcollege Current and Future Women Luminaries event, hosted by President @Alicegast
Registration: https://t.co/gMbFh3aftu

[Emily Day @EmilyD_stats]

Starting the week as a fully vaccinated individual 🥳🥳

[Victoria Cornelius @VR_Cornelius]

Inspired by a recent twitter post from @ADAlthousePhD
Nick Johnson finds himself mulling over adjustments for multiple testing. A blog by @nickjohnsonictu
https://t.co/h18FTJsTLj

[Hashim U. Ahmed @LondonProstate1]

IP4-CHRONOS (A).
Our last attempt to show whether randomised data can be collected for focal HIFU and cryotherapy compared to radical therapy.
Let’s see if all those calling for randomised data will support to recruit over next 6 months...

[Emily Day @EmilyD_stats]

Great way to end Thursday 👍🏻

[Imperial Prostate @IP_London]

A handy infographic of our recently published research

Full paper is open access and free for all 🔬📜🙌
👉https://t.co/xDlz1A4kjR

@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi

[JAMA Oncology @JAMAOnc]

Emerging evidence suggests that MRI could be a new screening test for #prostatecancer https://t.co/BPic9TnQh0 @eldredevans @LondonProstate1 @EmilyD_stats @ProfPadhani @HemmySokhi #PROSTAGRAM

[IP2 - ATLANTA Trial @AtlantaIp2]

Congratulations to the IP1-PROSTAGRAM Team for making it onto the front page of the Daily Telegraph 🙌🔬

Also widespread coverage in others newspaper
✅https://t.co/wc4OZ2MmxP

✅https://t.co/frmyPHrw3S

✅https://t.co/KTudSQtGVc

@EmilyD_stats @BurakPaula @eldredevans

[David Eldred-Evans @eldredevans]

Surreal to see our research on front page of @dailytelegraph. Thanks @PhoebeS1992

➡️ Read at https://t.co/xhPK5NStOo

@LondonProstate1 @HemmySokhi @SageOfLondon1 @ProfPadhani @EmilyD_stats

[The Guardian @guardian]

New prostate cancer scan 'could replace invasive exam and save lives' https://t.co/itXw5sIKsA

[Imperial Prostate @IP_London]

IP1-PROSTAGRAM just published in @JAMAOnc📢

“Short, non-contrast MRI may have favourable performance characteristics as a screening test”

➡️https://t.co/pfvbIxEWO5

@eldredevans @LondonProstate1 @HemmySokhi @ProfPadhani @Francy_lif @imperialurology @ImperialSandC @TUF_tweets

[Emily Day @EmilyD_stats]

Well done and great work @LondonProstate1 @eldredevans @Francy_lif @BurakPaula @HemmySokhi @ProfPadhani and many others 👏🏼

[Emily Day @EmilyD_stats]

The IP-1 PROSTAGRAM Study: https://t.co/DkQFb391EU via @JAMAOnc part of @JAMANetwork - comparing the performance of PSA testing, MRI, and ultrasonography as screening tests for prostate cancer in a prospective, population-based cohort study 👏🏼👏🏼